Fresh Tracks Therapeutics, Inc.
FRTX · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Market Cap | $5,198 | $4,212 | $18,473 | $19,121 |
| - Cash | $10,868 | $8,680 | $26,884 | $30,115 |
| + Debt | $0 | $49 | $69 | $511 |
| Enterprise Value | -$5,670 | -$4,419 | -$8,342 | -$10,483 |
| Revenue | $8,006 | $6,943 | $404 | $1,822 |
| % Growth | 15.3% | 1,618.6% | -77.8% | – |
| Gross Profit | $8,006 | -$7,100 | -$27,827 | -$9,394 |
| % Margin | 100% | -102.3% | -6,887.9% | -515.6% |
| EBITDA | -$5,648 | -$21,063 | -$39,383 | -$20,903 |
| % Margin | -70.5% | -303.4% | -9,748.3% | -1,147.3% |
| Net Income | -$5,694 | -$20,661 | -$39,521 | -$20,903 |
| % Margin | -71.1% | -297.6% | -9,782.4% | -1,147.3% |
| EPS Diluted | -0.96 | -7.36 | -22.14 | -38.37 |
| % Growth | 87% | 66.8% | 42.3% | – |
| Operating Cash Flow | -$4,343 | -$19,335 | -$36,148 | -$20,034 |
| Capital Expenditures | $0 | -$47 | -$36 | -$23 |
| Free Cash Flow | -$4,343 | -$19,382 | -$36,184 | -$20,057 |